Interferon β-lb (Betaseron) treatment of multiple sclerosis

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 353-413

  Knobler, Robert L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057703842     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (96)

1. McFarlin DE, McFarland HF. Multiple sclerosis. N Engl J Med 1982; 307: 1183-1188, 1246-1251.
2. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α-4-β-1 integrin. Nature 1992; 356:63-66.
3. Raine CS, Cross AH. Axonal dystrophy as a consequence of long-term demy-elination. Lab Invest 1989; 60:714-725.
4. Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982; 306:1529-1532.
5. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology 1995; 45: 1122-1126.
6. Knobler RL, Marini JC, Goldowitz D, Lublin FD. Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE. J Neuropathol Exp Neurol 1992; 51:36-39.
7. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeg-lumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33: 480-489.
8. Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: Implications for treatment trials. Ann Neurol 1994; 36(Suppl):S86-S90.
9. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
10. Paty DW. Magnetic resonance in multiple sclerosis. Curr Opin Neurol Neu-rosurg 1993; 6:202-208.
11. Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161-166.
12. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Arch Neurol 1990; 47:98-104.
13. Swirsky-Sacchetti T, Mitchell DR, Seward J, et al. Neuropsychological and structural brain lesions in multiple sclerosis: A regional analysis. Neurology 1992; 42:1291-1295.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status score (EDSS). Neurology 1983; 33:1444-1452.
15. Gonzalez C, Vinitski S, Lublin FD, et al. Tissue segmentation and volumetric measurements as a marker of disease activity in MS (abstract). Neurology 1995; 45(Suppl):4.
16. Paty DW, Li DKB, The IFNB Multiple Sclerosis Study Group. Interferon beta lb is effective in relapsing-remitting multiple sclerosis: MRI results of a multicenter randomized double blind, placebo controlled trial. Neurology 1993; 43:662-667.
17. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: A critical analysis. Mult Scler 1995; 1:37-47.
18. Sipe JC, Knobler RL, Braheny SL, et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984; 34:1368-1372.
19. Knobler RL, Panitch HS, Braheny SL, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 1984; 34:1273-1279.
20. Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-jS treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow up. J IFN Res 1993; 13:333-340.
21. The IFNB Multiple Sclerosis Study Group. Interferon beta IB is effective in relapsing remitting multiple sclerosis: Clinical results of a multicenter randomized double blind, placebo controlled trial. Neurology 1993; 43: 655-661.
22. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344:9-13.
23. Eldridge R, Anaylotos CP, Schlesinger S, et al. Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med 1984; 311:948-953.
24. Moser H. Leukoencephalopathies caused by metabolic disorders. In Koet-sier JC, ed. Demyelinating Diseases. Vinken PJ, Bruyn GW, Klawans HL, series eds. Handbook of Clinical Neurology, Revised Series 3. Amsterdam: Elsevier, 1985; 47:583.
25. Johns DR, et al. Pitfalls in the molecular genetic diagnosis of Leber hereditary optic neuropathy (LHON). Am J Hum Genet 1993; 53:916-920.
26. Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based twin study in multiple sclerosis. N Engl J Med 1986; 315:1638-1642.
27. McFarland HF. Twin studies and multiple sclerosis (editorial). Ann Neurol 1992; 32:722-723.
28. Compston A. The epidemiology of multiple sclerosis: Principles, achievements, and recommendations. Ann Neurol 1994; 36 (Suppl 2):S211-S217.
29. Zavala C, Morton NE, Rao DC, et al. Complex segregation analysis of diabetes mellitus. Hum Hered 1979; 29:325-333.
30. Kalman B, Lublin FD, Alder H. Mitochondrial DNA mutations in multiple sclerosis. Mult Scler 1995; 1:32-36.
31. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1:1313-1315.
32. Kahn SH, Knobler RL., McGeady SJ, et al. The incidence and specificity of allergies in patients with multiple sclerosis. J Neuroimmunol 1991; (Suppl 1): 184.
33. Boos J, Kim JH. Evidence for a viral etiology of multiple sclerosis latent viruses. In: Cook SD, ed. Handbook of Multiple Sclerosis, New York: Marcel Dekker, 1990:41-61.
34. Voskuhl RR, Robinson ED, Segal BM, et al. HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2 MBP, in multiple sclerosis. J Immunol 1994; 153:4834-4844.
35. Fujinami, RS. Virus-induced autoimmunity through molecular mimicry. In Raine CS, ed. Advances in Neuroimmunology. Ann NY Acad Sci 1988; 540: 210-217.
36. Martenson RE. Myelin: Biology and Chemistry. Boca Raton, FL: CRC Press, 1993.
37. Selmaj K, Brosnan CF, Raine CS. Expression of heat shock protein-65 by oligodendrocytes in vivo and in vitro: Implications for multiple sclerosis. Neurology 1992; 42:795-800.
38. Johnson HM, Russell JK, Pontzer CH. Superantigens in human disease. Sci Am 1992; 266(4):92-101.
39. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1991; 1:97-105.
40. Wisniewski HM, Bloom BR. Primary demyelination as a nonspecific consequence of a cell-mediated immune reaction: Bystander demyelination. J Exp Med 1975; 141:346-359.
41. Hofman FM, Hinton DR, Johnson K, et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607-612.
42. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-346.
43. + current expression in cultured oligodendrocytes. J Membr Biol 1991; 124:127-137.
44. Lublin FD, Marini JC, Perreault M, et al. Autoimmune inflammation of astrocyte transplants. Ann Neurol 1992; 31:519-524.
45. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo. Final Report. Neurology 1970; 20(Suppl): 1-59.
46. Myers LW. Treatment of multiple sclerosis with ACTH and corticosteroids. In: Rudick RA, Goodkin DE, eds. Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives. Heidelberg, Germany: Springer-Verlag, 1992:135-156.
47. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326:581-588.
48. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MR1 evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55:450-453.
49. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329:1764-1769.
50. Sanders DB, Scopetta C. The treatment of patients with myasthenia gravis. Neurol Clin 1994; 12(2):343-368.
51. Goldberg E, Kelley CL, Trantas F, et al. Urinary tract infection frequency in MS exacerbations. J Neuroimmunol 1994; 54:173.
52. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45(7): 1277-1285.
53. Isaacs A, Lindenmann J. Virus interference. I. The interferons. Proc R Soc Lond B Biol Sci 1957; 147:258-273.
54. Friedman RM. Interferons: A Primer. New York: Academic Press, 1981.
55. Rueda BR, Naivar KA, George EM, et al. Recombinant interferon-tau regulates secretion of two bovine endometrial proteins. J IFN Res 1993; 13: 303-309.
56. Charlier M, L’Haridon R, Boisnard M, et al. Cloning and structural analysis of four genes encoding interferon-omega in rabbit. J IFN Res 1993; 13: 313-322.
57. Soos JM, Subramaniam PS, Hobeika AC, et al. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol 1995; 155:2747-2753.
58. Fog T. Interferon treatment of multiple sclerosis patients: A pilot study. In: Boese A, ed. Search for the Cause of Multiple Sclerosis and Other Chronic Diseases of the Nervous System. Weinheim: Verlag Chemie, 1980:491-493.
59. 8 units per ml. J Gen Virol 1978; 39:541-543.
60. Volz MA, Kirkpatrick CH. Interferons 1992. How much of the promise has been realised? Drugs 1992; 43:285-294.
61. Durelli L. Effects of interferon alpha on cytokines and immune function in MS. In: Reder AT, ed. Interferon Therapy of Multiple Sclerosis. New York: Marcel Dekker, 1997, Chapter 12.
62. Neighbor PA, Bloom BR. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci USA 1979; 76:476-480.
63. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neu-ropharm 1994; 17(6):495-547.
64. Knobler RL. Systemic interferon therapy of multiple sclerosis: The pros. Neurology 1988; 38(Suppl 2):58-61.
65. Fox, C. Waiting for interferon. Harper’s, 1982; 265(September):32-46.
66. Jacobs L, O’Malley J, Freeman A, Ekes R. Intrathecal interferon in multiple sclerosis. Science 1981; 214:1026-1028.
67. Rice GPA, Woelfel EL, Talbot PJ, et al. Immunological complications in multiple sclerosis patients receiving interferon. Ann Neurol 1985; 18: 439-442.
68. Kastrukoff L, Oger i. Natural interferon alpha in the treatment of MS. In: Reder AT, ed. Interferon Therapy in Multiple Sclerosis. New York: Marcel Dekker, 1997, Chapter 11.
69. Camenga DL, Johnson KP, Alter M, et al. Systemic recombinant alpha 2 interferon therapy in relapsing remitting multiple sclerosis. Arch Neurol 1986; 43:1239-1246.
70. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893-895.
71. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987; 37:1097-1120.
72. Traugott U, Lebon B. Demonstration of alpha, beta and gamma interferon in active chronic multiple sclerosis lesions. In: Raine CS, ed. Advances in Neuroimmunology. Ann NY Acad Sci 1988; 540:309-311.
73. Lublin FD, Knobler RL, Kalman B, et al. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 1993; 16:267-274.
74. Jacobs L, Salazar AM, Herndon R, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986;2:1411-1413.
75. Jacobs L, Salazar AM, Herndon R, et al. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: Results of a multicenter, double-blinded study. Arch Neurol 1987; 44:589-595.
76. Joseph J, Knobler RL, D’lmperio C, Lublin FD. Down-regulation of interferon gamma induced class II expression on human glioma cells by recombinant interferon beta: Effects of dosage treatment schedule. J Neuroimmunol 1988; 20:39-44.
77. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-154.
78. Antel J, Arnason BGW, Medof ME. Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity. Ann Neurol 1979; 5: 338-342.
79. Noronha A, Toscas A, Arnason BGW, et al. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990; 27:207-210.
80. Witt P. In: Reder AT, ed. Interferon Therapy in Multiple Sclerosis. New York: Marcel Dekker, 1997, Chapter 3.
81. Borden EC, Hawkins MJ, Sielaff KM, et al. Clinical and biological effects of recombinant interferon beta administered intravenously daily in phase I trial. J IFN Res 1988; 8:357-366.
82. Spear GT, Paulnock DM, Jordan RL, et al. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta interferon. Clin Exp Immunol 1987; 69:107-115.
83. Basham TY, Merigan TC. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol 1983; 130:1492-1494.
84. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-lb. Neurology 1995; 45:2173-2177.
85. Knobler RL, Greenstein JI, Johnson KP, et al. A pilot trial of recombinant human beta interferon in the treatment of relapsing-remitting multiple sclerosis. In Gonsette RE, Delmotte P, eds. Recent Advances in Multiple Sclerosis Therapy. Amsterdam: Elsevier 989:121-124.
86. Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
87. Antonelli G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiviral Res 1994; 24: 235-244.
88. Huber C, Batchelor JR, Fuchs D, et al. Immune response associated production of neopterin release from macrophages primarily under control of interferon gamma. J Exp Med 1984; 160:310-316.
89. Johnson KP, Knobler RL, Greenstein J, et al. Recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis: Pilot study results. Neurology 1990; 40(Suppl 1):261.
90. 89a. Sibley WA, Ebers GC, Panitch HS, Reder AT, van den Noort S. Interferon beta treatment of multiple sclerosis. Reply from the authors. Neurology 1994 ; 44:186-190.
91. Arnason BGW. Interferon beta in multiple sclerosis. Neurology 1993; 43: 641-643.
92. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994; 44:1537-1540.
93. Birk K, Ford C, Smeltzer S, et al. The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990; 47:738-742.
94. Betaseron (Interferon beta-lb). Package insert. Berlex Laboratories, Richmond, CA, 1995.
95. Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34:365-367.
96. Braverman IM, Yen A. Demonstration of immune complexes in spontaneous and histamine-induced lesions and in normal skin of patients with leukocy-toclastic angitis. J Invest Dermatol 1975; 64:105-112.